Severe hepatotoxicity during treatment with capmatinib.
Carmen María Valencia SotoVirginia Martínez CallejoAdela García-Avello Fernández-CuetoMaría Victoria Villacañas PalomaresSara Barbadillo VillanuevaMaría Ochagavía SufrateguiMarta Francisca López-Brea PiquerasMarta Valero DomínguezPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)
The recognition and diagnosis of drug-induced liver injury (DILI) are often difficult and delayed. Molecularly targeted agents require careful assessment of liver function both prior to and during therapy. Capmatinib hepatotoxicity is an infrequent but severe adverse drug reaction (ADR). Prescribing information includes recommendations about liver function monitoring. The main approachment for DILI is the removal of the causative agent. Detection and communication of ADRs to the Pharmacovigilance Systems have special relevance for novel drugs, with little data in real life setting.